Introduction
============

Since the 1980s, there has been an alarming increase in group A *Streptococcus* (GAS)^1^-mediated severe invasive disease (SID) around the world [1](#R1){ref-type="bib"} [2](#R2){ref-type="bib"} [3](#R3){ref-type="bib"} [4](#R4){ref-type="bib"} [5](#R5){ref-type="bib"}. Streptococcal invasive disease may include soft tissue infections, such as cellulitis, and necrotizing fasciitis or deeper infections, such as septic scarlet fever (SF) and bacteremia [6](#R6){ref-type="bib"}. The most severe form of invasive infection results in clinical symptoms similar to those seen in patients with toxic shock syndrome (TSS) caused by *Staphylococcus aureus* and was therefore described as streptococcal toxic shock--like syndrome (STLS) [7](#R7){ref-type="bib"} [8](#R8){ref-type="bib"}. Characteristic symptoms of STLS include hypotension or shock, fever, rash, renal impairment, vomiting, and diarrhea [9](#R9){ref-type="bib"}. The multiorgan involvement in STLS suggests that a toxin produced by *Streptococcus pyogenes* might be involved in pathogenesis. Prime candidates are the streptococcal pyrogenic exotoxins (SPEs), a family of highly mitogenic proteins secreted individually or in certain combinations by many *S*. *pyogenes* strains. Together with the staphylococcal enterotoxins (SEs) and the toxic shock syndrome toxin (TSST), they belong to a large family of proteins, also known as bacterial superantigens (SAgs), with similar amino acid sequence, protein structure, and functional activities [10](#R10){ref-type="bib"} [11](#R11){ref-type="bib"}. SAgs simultaneously bind to MHC class II antigens and TCR molecules and thereby stimulate a large number of T cells in a TCR Vβ--specific mode. This event leads to the release of high systemic levels of cytokines, such as TNF-α and IL-1β, and of T cell mediators like IL-2 and IFN-γ [12](#R12){ref-type="bib"} [13](#R13){ref-type="bib"} [14](#R14){ref-type="bib"}.

It has also been suggested that bacterial SAgs are implicated in other diseases, such as acute rheumatic fever and Kawasaki disease (KD) [6](#R6){ref-type="bib"} [15](#R15){ref-type="bib"} [16](#R16){ref-type="bib"}. SPE-A has long been associated with the ability of GAS to cause SF and STLS, and is believed to be the primary cause of the skin rash in SF [8](#R8){ref-type="bib"} [17](#R17){ref-type="bib"} [18](#R18){ref-type="bib"}. Although it has been shown that SPEs can cause pathological conditions including fever and shock [19](#R19){ref-type="bib"} and that severe streptococcal infections are associated with certain exotoxin-producing strains [17](#R17){ref-type="bib"} [20](#R20){ref-type="bib"} [21](#R21){ref-type="bib"}, a correlation between disease and a particular exotoxin and/or *S*. *pyogenes* strain remains elusive. Yu and Ferretti performed molecular epidemiologic analysis on 300 general *S*. *pyogenes* clinical isolates (from patients with a variety of diseases, except SF) and found the *speA* gene with a frequency of only 15% [21](#R21){ref-type="bib"}. Among 146 isolates from patients with SF, 45% were shown to contain *speA*. Hauser et al. analyzed 34 *S*. *pyogenes* isolates from patients with STLS and found the *speA* gene in 85%. The *speC* gene was found in only 21% of the isolates [20](#R20){ref-type="bib"}. Several investigators reported a correlation between STLS and serotypes M1, M3, T3, and M12 and that *speA* was mostly, but not exclusively, found in M1- and M3-type strains from patients with SF [17](#R17){ref-type="bib"} [20](#R20){ref-type="bib"} [21](#R21){ref-type="bib"}. On the other hand, a genetic and phenotypic diversity among *S*. *pyogenes* isolates from severe invasive infections and STLS was reported in the United States [22](#R22){ref-type="bib"}, and Forni et al. found an M-nontypable (MNT) strain to be common in STLS patients [9](#R9){ref-type="bib"}. Furthermore, Hsueh and co-workers found no association of severe invasive disease in Taiwan with any SPE [23](#R23){ref-type="bib"}.

Four allelic variants of the *speA* gene have been found in *S. pyogenes* so far [24](#R24){ref-type="bib"}. The *speA1* allele occurs in many distinct clonal lines, but expression of SPE-A2 and SPE-A3, which are characterized by single amino acid substitutions, was shown in two single clones that have caused the majority of STLS episodes in the last decade [24](#R24){ref-type="bib"} [25](#R25){ref-type="bib"}. Musser et al. reported that all contemporary strains assigned to electrophoresis types (ETs) 1 and 2 (two highly pathogenic clones, which generally express serotype M1 and M3, respectively) have the *speA2* and *speA3* allelic variants, respectively [25](#R25){ref-type="bib"}. In contrast, ET1 and 2 isolates from disease episodes in the 1920s and 1930s contain the *speA1* allele, suggesting temporal variation. Kline and Collins showed that SPE-A3 has a significantly increased mitogenic activity and MHC class II affinity compared with SPE-A1 and SPE-A2 [26](#R26){ref-type="bib"}. These results suggest that SPE-A3 represents a more active form of SPE-A and might explain the fluctuation in severity and disease frequency of severe invasive infections.

The implication of other exotoxins, like SPE-C and SSA, in streptococcal infections is even less clear and is assumed on the basis that not all cultures from patients with STLS or other severe invasive diseases express SPE-A.

Since some cases of SID cannot be correlated to any of the known SPEs, there is a suggestion that one or more novel SPEs might play a role in the resurgence of SID in recent years. Recently, we reported the identification of the streptococcal exotoxins SMEZ-2, SPE-G, SPE-H, and SPE-J [27](#R27){ref-type="bib"}. SMEZ-2 is an allelic variant of the previously described SMEZ [28](#R28){ref-type="bib"}. Functional analysis using recombinant protein revealed that SPE-G and SPE-H target human T cells carrying the Vβ2 region, a specificity they share with SPE-C and TSST. SMEZ and SMEZ-2 target human Vβ4 and Vβ8 T cells, a unique specificity among streptococcal SAgs. A selective expansion of Vβ2 and Vβ8 T cells has been reported in patients with KD [15](#R15){ref-type="bib"}, but the potential role of SAgs in triggering this disease remains unclear.

In this report, we present evidence for wide genotypic variation in SMEZ among a panel of 103 clinical isolates selected to provide a spectrum of distinct M/emm types occurring in the community and to provide representation of subtypes within specific M types. Thus far, 24 *smez* alleles have been identified in 22 different M/emm types. Moreover, the frequency of *smez* in 95 analyzed GAS isolates approached 100%, making it the most common of all known *sag* genes, at least within New Zealand. Given the fact that SMEZ is also the most potent SAg produced by *S*. *pyogenes*, this has significant implications for its involvement in *Streptococcus*-mediated disease.

Materials and Methods
=====================

Bacterial Isolates.
-------------------

The 103 streptococcal isolates were obtained from the Institute of Environmental Science and Research in Porirua, New Zealand. Group 1 consists of 52 isolates (including 5 β-hemolytic non-GAS strains) that were taken from various parts of New Zealand between 1976 and 1996. Group 2 contains 51 isolates (including 4 non-GAS) collected from South Auckland schools in 1998. The non-GAS were *Streptococcus agalactiae* (group B), *Streptococcus equis* (group C), and *Streptococcus spp.* (group G). Genotyping of all isolates was undertaken blinded to their strain definition. Two duplicates were included to ensure accuracy of the testing. The results of the duplicate isolates were not included in the overall statistics.

Genomic DNA Preparation.
------------------------

All *S*. *pyogenes* isolates were grown overnight in 10 ml of Brain Heart Infusion medium (BHI; Difco) at 37°C in 15-ml Falcon tubes without agitation. The cells were pelleted and washed in 1 ml of lysis buffer (10 mM Tris, pH 8, 50 mM EDTA) in a 1.5-ml Eppendorf tube and finally resuspended in 400 μl lysis buffer. 4 U of mutanolysin (Sigma-Aldrich), 2 mg of lysozyme, and 40 μg of RNaseA (Sigma-Aldrich) were added. After incubating the samples for 1 h at 37°C with gentle agitation, 20 μg of proteinase K (Sigma-Aldrich) was added and incubated for an additional 30 min. Then, 40 μl of a 20% sarcosyl solution was added, and the DNA was extracted with phenol/chloroform and finally precipitated with ethanol. The DNA was resuspended in 50 μl of TE buffer.

Genotyping of S. pyogenes Isolates.
-----------------------------------

Purified genomic DNA from all *S*. *pyogenes* isolates was used for PCR with specific primers for the *smez*, *spe-g*, and *spe-h* genes as described previously [27](#R27){ref-type="bib"}. In addition, a primer pair specific to a DNA region encoding the 23S rRNA, oligo 23rRNA fw (GCTATTTCGGAGAGAACCAG) and oligo 23rRNA rev (CTGAAACATCTAAGTAGCTG), was designed and used for PCR as a positive control.

Southern Blot Analysis.
-----------------------

About 5 μg of genomic DNA was digested using restriction enzyme HindIII (GIBCO BRL) and loaded onto a 0.7% agarose gel. The DNA was transferred from the gel to a Hybond-N+ nylon membrane (Amersham Pharmacia Biotech) as described by Maniatis et al. [29](#R29){ref-type="bib"}. A 640-bp DNA fragment of the *smez-2* gene was radiolabeled using the RadPrime Labeling System (GIBCO BRL) and \[α-^32^P\]dCTP (NEN Life Science Products). The nylon blots were hybridized with the radiolabeled probe in 2× SSC, 0.5% SDS, 5× Denhardt\'s overnight at 65°C. After washing twice in 0.2× SSC, 0.1% SDS at 65°C, the blots were analyzed on a Storm PhosphorImager^®^ (Molecular Dynamics).

Cloning and Sequencing of smez Alleles.
---------------------------------------

All PCR products obtained from genotyping with different *S*. *pyogenes* isolates were enriched using the Wizard PCR DNA purification system (Promega) and cloned into T-tailed pBlueScript SKII vectors (Stratagene) followed by transformation into *Escherichia coli* XL1 blue.

The *smez* genes were analyzed by the dideoxy chain termination method using a Licor automated DNA sequencer (model 4200). Three subclones of every cloning experiment were analyzed to insure that no Taq polymerase--related mutations were introduced. The DNA sequences of the *smez* alleles have been annotated in EMBL/GenBank/DDBJ. The accession numbers are listed in [Table](#T2){ref-type="table"}.

Expression and Purification of Recombinant SMEZ Proteins.
---------------------------------------------------------

Recombinant toxins were produced as described previously [27](#R27){ref-type="bib"}. In brief, individual *smez* genes were cloned from pBlueScript vector into the BamHI-EcoRI cloning site of pGEX-2T expression vector and transformed into *E*. *coli* DH5 cells. For expression of glutathione *S*-transferase (GST) fusion proteins, the DH5 cells were grown in tryptone phosphate medium at 30°C and induced with 0.1 mM isopropyl-β-[d]{.smallcaps}-thiogalactopyranoside (IPTG) at OD~600~ of 0.7--0.9. The GST fusion proteins were purified on glutathione (GSH) agarose. The mature proteins were then cleaved off from GST by trypsin digestion and further purified by two rounds of cation exchange chromatography. Due to their low isoelectric point, some SMEZ alleles could not be separated from GST by this method. In these cases, trypsin cleavage was performed on the GSH agarose and the mature toxins were eluted from the column.

Toxin Proliferation Assay.
--------------------------

Human PBLs were purified from blood of a healthy donor by Histopaque Ficoll (Sigma-Aldrich) fractionation. The PBLs were incubated in 96-well round-bottomed microtiter plates at 10^5^ cells per well with RPMI-10 (RPMI with 10% FCS) containing varying dilutions of recombinant toxins. The dilution series was performed in 1:5 steps from a starting concentration of 10 ng/ml of toxin. After 3 d, 0.1 μCi \[^3^H\]thymidine was added to each well and cells were incubated for an additional 24 h. Cells were harvested and counted on a scintillation counter.

Jurkat Cell Assay.
------------------

Jurkat cells (a human T cell line) and LG-2 cells (a human B lymphoblastoid cell line, homozygous for HLA-DR1) were harvested in log phase and resuspended in RPMI-10. 100 μl of the cell suspension, containing 1 × 10^5^ Jurkat cells and 2 × 10^4^ LG-2 cells, was mixed with 100 μl of varying dilutions of recombinant toxins on 96-well plates. After incubating overnight at 37°C, 100 μl aliquots were transferred onto a fresh plate and 100 μl (1 × 10^4^) of SeI cells (IL-2--dependent murine T cell line) per well was added. After incubating for 24 h, 0.1 μCi \[^3^H\]thymidine was added to each well and cells were incubated for an additional 24 h. Cells were harvested and counted on a scintillation counter. As a control, a dilution series of IL-2 was incubated with SeI cells.

For detection of native Vβ8-specific exotoxin expression in *S*. *pyogenes*, each isolate was grown in 10 ml of BHI medium overnight at 37°C. Cells were then removed by centrifugation and supernatants were diluted 1:10, 1:50, 1:250, and 1:1,000 in RPMI-10, and the assay was continued as described above.

Neutralization Assay.
---------------------

PBLs were obtained and stimulated as described under Toxin Proliferation Assay above, with the exception that the 10% FCS was replaced by 10% human serum from various healthy donors. All stimulations were done using 40 pg/ml of recombinant toxin. PBLs from a single donor were used for all tests. The neutralizing response was determined by comparing the T cell proliferation with a control test using 10% FCS instead of 10% human serum. The mitogenic response obtained in the absence of human serum was set to 100%.

Results
=======

Genotyping of S. pyogenes Isolates.
-----------------------------------

PCR-based genotyping was performed in order to determine the frequency of the recently identified *sag* genes *smez*, *spe-g*, and *spe-h* in streptococcal isolates ([Table](#T1){ref-type="table"}). The PCR primers for *smez* were designed to anneal with both genes, *smez* and *smez-2*. The 103 isolates were collected in New Zealand between 1976 and 1998 from varying sites in patients with varying infections, although the majority were from sore throats. They comprised 94 GAS and 9 non-GAS, which were *S*. *agalactiae* (group B), *S*. *equis* (group C), and *Streptococcus spp*. (group G). There are 22 distinct M/emm types represented among the GAS isolates, 13 isolates are MNT, and in 2 cases the M type is unknown. The analysis was undertaken blinded to the details of each isolate, and two duplicate isolates were included (95/31 and 4202) to demonstrate the reproducibility of the testing procedure. The isolates are listed in two groups. Group 1 contained isolates collected within a large time frame (1976--1996) from all over New Zealand. Group 2 comprised isolates collected within a short time (1998) in a distinct area (South Auckland schools).

All of the nine non-GAS isolates (belonging to groups B, C, and G) were negative for the tested *sag* genes. The frequencies for *smez*, *spe-g*, and *spe-h* within the GAS isolates were 95.6, 100, and 23.9%, respectively. A correlation between a certain M/emm type and the presence of the *spe-h* gene could not be established. The deficiency in this current set was that only five M/emm types were represented by more than one isolate. The most frequent serotype was M/emm12 with 13 isolates, from which 7 were positive and 6 were negative for *spe-h*, suggesting genetic diversity within the M/emm12 strain. In contrast, all 12 tested NZ1437/M89 isolates were negative for *spe-h*.

The high frequencies of *smez* and *spe-g* are of particular interest, as this has not been described for any other streptococcal *sag* gene thus far. Other *spe* genes, like *speA*, *speC*, and *ssa*, are found at much lower frequencies, and horizontal gene transfer might explain the varying frequencies of these genes in different strains. In contrast, both *smez* and *spe-g* were found in virtually all tested GAS isolates. Only four GAS isolates (11152, 11070, 94/229, and 11610) tested negative for *smez*. These were PT2612, emm65, M49, and emm57. Southern hybridization was performed to find out if the negative PCR results were due to lack of the *smez* gene or to lack/alteration of the primer binding site(s). HindIII-digested genomic DNA of selected streptococcal isolates was probed with a 640-bp radiolabeled *smez-2* PCR fragment ([Fig. 1](#F1){ref-type="fig"}). The *smez* gene is located on a 1953-bp HindIII DNA fragment in the M1 strain (700294; American Type Culture Collection) corresponding to fragment A in the Southern blot. In all four PCR-negative isolates, the *smez* probe hybridized to a HindIII fragment of ∼4 kb (fragment B), but not to the smez bearing fragment A (samples 17, 26, 57, and 67). In addition, the smez probe bound to a second DNA fragment of ∼4.2 kb (fragment C) in isolate 11152 (sample 17). In the M1 reference strain (lane 1) and in isolate 4202 (sample 50), the smez probe also bound to fragment B, in addition to fragment A. Fragment B in the M1 strain contains a 180-bp region that shares 97% sequence homology with the 3′ end of the *smez* gene. These results suggest that the four PCR-negative isolates possess a truncated *smez* gene or a *smez-*like sequence, but not a complete *smez* gene.

Identification of Multiple smez Alleles.
----------------------------------------

DNA sequence analysis of the *smez* genes from different *S*. *pyogenes* isolates was performed. 37 isolates were analyzed, representing 22 M/emm types, 5 MNT isolates, and 2 isolates of unknown M type ([Table](#T2){ref-type="table"}). 23 different alleles were identified, bringing the total number of *smez* alleles to 24 (*smez* is hereafter referred to as *smez-1*). The *smez* gene appears to be in linkage equilibrium with the M/emm type. Only three *smez* alleles (*smez-3*, *smez-4*, and *smez-8*) were found in more than one M/emm type. *smez-3* was found in all three tested M/emm12 type isolates plus one MNT. *smez-4* was found in one M5 and in one PT180. *smez-8* was found in one M4 and in one M81 type strain. Four of the five MNT isolates carry *smez-6* and one carries *smez-3*.

With the exception of *smez-6*, *smez-19*, and *smez-23*, which have individual single base pair deletions causing frame shifts, all *smez* alleles possess complete open reading frames. *smez-2*, which was isolated from a separate strain, was not found in any of the current panel of isolates. The 21 intact *smez* genes encode 21 different SMEZ variants.

Sequence identities between *smez* alleles are between 94.5 (*smez-1* and *smez-2*) and 99.9% (equivalent to one base pair difference), e.g., *smez-4* and *smez-7*. A family tree of the 24 *smez* alleles was established based on DNA sequence homology ([Fig. 2](#F2){ref-type="fig"}). The *smez* alleles were grouped into two clusters. Group A comprises *smez-1*, *smez-5*, *smez-8*, *smez-10*, *smez-12*, and *smez-15*. All other *smez* alleles are in group B. Sequence variation between all *smez* alleles is restricted to only 62 nucleotide positions, or 9.8% of the coding region for the mature protein ([Table](#T2){ref-type="table"}). Most of the variations are G/A and T/C transitions, while transversions only occur at position 290 (A/C), 291 (A/T), and 358 (G/C). 31 of the variable positions (50%) result in amino acid changes; the other 50% are silent exchanges. The frequency of a nucleotide exchange at a particular position also varies significantly within the 24 *smez* alleles. 17 of the 62 sites are point mutations for single alleles, while the remaining 45 sites are point mutations common to 2 or more alleles. The most variable sites are positions 231, 234, and 238 and occur in 12 alleles (50%). Some of these highly variable nucleotides are linked together and build five distinct regions ([Table](#T3){ref-type="table"}). One region (III) comprising 10 polymorphic sites between nucleotide 282 and 298 occurs in only 2 combinations within the 24 *smez* alleles. These combinations segregate the two main groups of the *smez* family tree. The other four blocks are less conserved, and sequence combinations between these blocks occur in several alleles, generating gene mosaics. Interestingly, the polymorphic sequence blocks are more frequent in the center of the gene, between nucleotide positions 231 and 427. Only one polymorphic block (V) is in the last third of the gene. No blocks occur in the first third. The sequence clusters and mosaic distribution are also reflected in the amino acid sequence ([Table](#T4){ref-type="table"}). Interestingly, the five polymorphic amino acid positions within block III are all between amino acid positions 91 and 100 and are therefore clustered closer together than in the other blocks. The amino acid composition of this polymorphic block influences the isoelectric point of the SMEZ variants. All group A variants have a pI between 5.02 and 5.4, whereas the pIs of group B SMEZ are between 5.73 and 9.62 ([Table](#T2){ref-type="table"}).

Expression of SMEZ Variants by S. pyogenes Isolates.
----------------------------------------------------

Both SMEZ-1 and SMEZ-2 specifically target human Vβ8-bearing T cells [27](#R27){ref-type="bib"}. Jurkat cells (a Vβ8 T cell line) were used to determine SMEZ expression from *S*. *pyogenes* culture supernatants from all 103 streptococcal isolates (see Materials and Methods). 62 isolates (66% of the GAS isolates) showed Vβ8-stimulating activity. No Vβ8 activity was detected from the nine non-GAS, the four *smez* PCR-negative GAS strains, and the isolates carrying the pseudogenes *smez-6*, *smez-19*, or *smez-23*. These results suggest that SMEZ is the only Vβ8-targeting SAg in *S*. *pyogenes*. Culture supernatant from 12 isolates with complete open reading frames for *smez* did not stimulate Jurkat cells. These isolates possess *smez-5*, *smez-10*, *smez-12*, *smez-18*, *smez-20*, *smez-21*, or *smez-22*. These results suggest the following possibilities: (a) those isolates do not express SMEZ under the selected growth conditions; (b) mutations outside the *smez* coding region repress gene expression; or (c) these isolates express SMEZ variants that have lost their specificity to target Vβ8 T cells. Recombinant SMEZ variants were generated in *E*. *coli* using the GST expression system.

Successful recombinant expression was achieved for rSMEZ-3, rSMEZ-5, rSMEZ-7, rSMEZ-8, rSMEZ-9, rSMEZ-13, rSMEZ-20, rSMEZ-21, and rSMEZ-22. Fusion proteins were completely soluble and gave yields of ∼30 mg/liter. The purified recombinant toxins were applied to isoelectric focusing ([Fig. 3](#F3){ref-type="fig"}). Isoelectric points between SMEZ variants were consistent with the calculated pIs ([Table](#T2){ref-type="table"}).

Native conformation of the recombinant toxins was confirmed by human T cell proliferation assay. All purified SMEZ variants were active on human T cells with similar half-maximal responses (P~50~ values) between 0.09 and 0.3 pg/ml, except for rSMEZ-5 with a P~50~ of 0.7 pg/ml, and rSMEZ-10 and rSMEZ-12, which gave P~50~ values of 2 and 15 pg/ml, respectively ([Table](#T2){ref-type="table"}).

rSMEZ-5, rSMEZ-20, rSMEZ-21, and rSMEZ-22 all stimulated Jurkat cells ([Fig. 4](#F4){ref-type="fig"}), thus confirming that the lack of Vβ8-stimulating activity of wild-type streptococcal culture supernatants is due to lack of expression rather than altered Vβ specificity of the SMEZ variants produced.

Antigenic Variation in SMEZ Variants.
-------------------------------------

Human sera from 100 healthy donors were tested for the presence of naturally acquired neutralizing antibodies to SMEZ variants rSMEZ-1, rSMEZ-2, rSMEZ-3, rSMEZ-5, rSMEZ-7, rSMEZ-8, rSMEZ-9, rSMEZ-13, rSMEZ-20, rSMEZ-21, and rSMEZ-22. The neutralizing response was determined as the percentage of inhibition of T cell stimulation by SMEZ in the presence of 10% human serum versus 10% FCS. More than 75% inhibition was defined as full, 30--75% as moderate, and \<30% as negative neutralization.

85 sera fully neutralized the activity of all 11variants tested. The remaining 15 sera displayed only partial neutralizing activity on a subset of the variants. 20 sera were selected for a repeat test, and the confirmed results are shown in [Table](#T5){ref-type="table"}. Seven sera (26, 32, 39, 73, 86, 99, and 100) displayed very different neutralizing response profiles, suggesting the existence of variant (epitope) specific antibodies. For example, serum 86 strongly neutralized rSMEZ-1 and rSMEZ-5, but none of the other variants. Interestingly, both SMEZ-1 and SMEZ-5 belong to group A and share a common amino acid stretch in region III ([Table](#T4){ref-type="table"}). However, serum 86 did not effectively neutralize another group A variant, rSMEZ-8. The only amino acid differences between SMEZ-1, SMEZ-5, and SMEZ-8 that could explain this different neutralization are residues D62A, M68V (both in region I), and P117T (in region VI). Thus, for serum 86, the likely neutralizing epitopes must include one of these three residues.

Serum 39 was similar to serum 86, and sera 73 and 75 also neutralized rSMEZ-8--stimulated T cells. SMEZ-1 and SMEZ-5 were commonly neutralized by most of the sera tested. Only two sera (30 and 31) displayed less than complete neutralization responses. In contrast, SMEZ-2 activity was not inhibited by eight sera, and another six sera showed only moderate inhibition. SMEZ-2 was therefore the least commonly neutralized variant.

Discussion
==========

SMEZ is the most potent bacterial SAg so far discovered, with specificity towards Vβ4- and Vβ8-bearing human T cells. Unlike all other SAgs, SMEZ is highly polymorphic, having arisen from genetic mosaicism at a single genetic locus. 22 different *smez* alleles were found in 21 different M-type positive GAS isolates obtained over a 15-yr period throughout New Zealand, in addition to the 2 alleles, *smez* and *smez-2*, described previously [27](#R27){ref-type="bib"} [28](#R28){ref-type="bib"}. All of the 94 isolates tested positive for the *smez* gene by PCR or Southern analysis. Thus, *smez* is not only the most potent SAg, it is also the most prevalent. The polymorphism in the SMEZ protein results in antigenic variants that are not consistently neutralized by naturally occurring antibodies present in normal adult human sera, yet the human TCR β chain profile remains steadfastly Vβ4 and Vβ8.

Genetic Mosaicism.
------------------

The variation in *smez* has most likely arisen through gene mosaicism, and the strongest indicator for this is that 30 out of 31 polymorphic positions have only 2 possible amino acids. The mechanism for gene mosaics is homologous recombination between two copies of a gene, and Southern blot analysis shows that some isolates indeed carry a second *smez* gene or *smez-*like sequence. However, homologous recombination of *smez-1* with the *smez-*like sequence on the M1 genome would result in another pseudogene due to a nonsense mutation within the *smez-*like sequence. Moreover, \>2 homologous genes would be needed to generate the mosaic pattern seen in the 24 *smez* alleles. The different sequence segments appear to have originated from different strains, suggesting the possibility of intergenic recombination with a horizontally transferred homologous gene from another strain. Interstrain transfer followed by homologous recombination has been reported to play a key role in the evolution of *emm-*like genes [30](#R30){ref-type="bib"}, indicating that such a mechanism exists in *S*. *pyogenes*.

Sequence combination between different alleles is not the only mechanism to create variability in the *smez* gene. 11 of the 31 variable residues of the SMEZ variants correlate with individual point mutations for single alleles and must have occurred independently in the respective strains. This is also remarkable, given the fact that such a high mutation rate is not observed in any other *sag* genes, including *spe-g*, which was also found in all isolates tested. It is possible that point mutations in other *sag* genes are eliminated by selective pressure in order to maintain functionality of the toxin. However, this seems unlikely, since the variant residues in SMEZ do not contribute to the overall structure and are not conserved within the SAg family.

Allelic variation has been described for the staphylococcal enterotoxin C (SEC). SEC1 and SEC2 differ by only seven amino acid residues, but target a different set of TCR [31](#R31){ref-type="bib"}. Also, SEA and SEE, which still share 85% amino acid sequence identity, vary in their TCR specificity [32](#R32){ref-type="bib"}.

Protein expression of a Vβ8-stimulating toxin was observed in the culture supernatant of 66% of the GAS isolates. No Vβ8 activity was found in any of the isolates that carry a defective *smez* gene, suggesting that *smez* is the only Vβ8-specific toxin in *S*. *pyogenes*. Since the *smez* gene has been analyzed in only a fraction of the GAS panel, it is possible that more nonfunctional *smez* alleles occur in the natural *S*. *pyogenes* population. Of the identified complete *smez* genes, 7 out of 21 did not express the SMEZ protein, suggesting a tight control of gene transcription. However, it is important not to assume that expression under in vitro conditions always equates to expression in vivo. Interestingly, the SMEZ-producing strains include M1, M4, and M12 types. These are connected to STLS [33](#R33){ref-type="bib"}, whereas the SMEZ-13--producing NZ1437/M89 type strain is connected to rheumatic fever in New Zealand [34](#R34){ref-type="bib"}. A larger panel of GAS isolates, in particular those known to cause invasive diseases, must be analyzed for SMEZ expression to identify any connection between expression of a certain SMEZ variant and streptococcal diseases.

Antigenic Variation.
--------------------

There are 31 variable amino acid positions in SMEZ. Analysis of a recent SMEZ-2 crystal structure shows that 26 of these residues are surface exposed and scattered across the entire protein. Only five of the variable positions have side chains that are buried, and all are conservative changes, indicating that there has been selective pressure to vary the surface of the molecule while preserving structural integrity of the molecule [34a](#R34a){ref-type="bib"}. Widespread prevalence of SMEZ-producing strains of *S*. *pyogenes* in the normal adult human population was confirmed by seroconversion in 100/100 normal healthy young adults. However, 15% of the sera showed only partial neutralization profiles against a panel of recombinant SMEZ variants. SMEZ-1 was the most commonly neutralized, whereas SMEZ-2 was the least. SMEZ-2 is a rare variant that has not yet been found in any *S*. *pyogenes* isolate in New Zealand. SMEZ-2 was identified in a single isolate of unknown M/emm type from a patient with rheumatic fever in the United States, and is the most potent variant known to date [27](#R27){ref-type="bib"}. In contrast, SMEZ-1 was found associated with the M1 strain, a very common strain in New Zealand. These data suggest that certain SMEZ variants are better capable of generating a generic protective neutralizing response against all SMEZ variants than others, and that protective antibodies offer only partial protection against a subset of SMEZ variants. This raises an interesting question of whether individual SMEZ variants are linked to disease severity. Screening patients with severe streptococcal-mediated disease for lack of seroconversion against individual SMEZ variants might provide information in this regard.

The strong linkage between the *smez* gene and the *emm* gene, which codes for the major polymorphic surface antigen M protein, offers one explanation for the mechanisms of *smez* genetic variation. The *smez* gene is located 14 kb upstream from the Vir regulon. The M protein represents the major neutralizing surface antigen on *Streptococci*, and generation of diversity in the M protein antigenic determinants might also affect neighboring genes. Thus far, we have analyzed only 21 different M/emm types for the *smez* gene. It is likely that the actual number of *smez* alleles among the *S*. *pyogenes* population is much higher. This might be of particular interest, as the epidemiology of streptococcal disease appears to be connected to certain M types, and temporal shifts in prevalence of certain M types occur [35](#R35){ref-type="bib"}.

Role of SMEZ.
-------------

SAgs interfere with host adaptive immune responses, driving profound Th1-type responses in an antigen-nonspecific way characterized by high levels of INF-γ, IL-2, and nonspecific T cell proliferation. How this response improves survival of the bacteria has yet to be clearly established, but one might argue that the prime function is to prevent the production of high affinity cytotoxic antibodies by promoting a cellular, Th1-mediated response. The high degree of antigenic variation is good evidence that SMEZ provides a significant growth advantage for *S*. *pyogenes* and that the variation at this locus has been driven primarily by the need to escape antibody neutralization, rather than through a need to expand its T cell repertoire.

Retention of the TCR Specificity.
---------------------------------

In contrast to the antigenic diversity, the TCR Vβ binding site of SMEZ appears to be unaffected by surrounding amino acid variation. One conclusion to draw from this is that Vβ4- and Vβ8-bearing T cell subsets are uniquely important in host defence against *Streptococci*. However, one could also argue that retention of this T cell specificity is due to the physical constraints of the SMEZ--TCR β chain interaction, so that other TCR β chains cannot be effectively accommodated without loss of SAg activity. However, the fact that SMEZ effectively targets murine TCR β chains [27](#R27){ref-type="bib"} suggests that there are no special constraints on the SMEZ--TCR binding site. Why SMEZ should be privy to such extensive variation while all other SAgs are substantially invariant is unclear, but does point to an important role of this particular SAg in the survival of all group A *Streptococci*. There are examples of allelic variation in other streptococcal SAgs, such as SPEA [24](#R24){ref-type="bib"}, SPE-C [36](#R36){ref-type="bib"}, and SSA [37](#R37){ref-type="bib"}, but to a much lesser degree and without the mosaicism seen at the *smez* locus. Genes with mosaic structures are known in other pathogenic organisms such as streptokinase (*skn* [38](#R38){ref-type="bib"}), the *emm-like* genes [30](#R30){ref-type="bib"}, or the *Streptococcus pneumoniae* autolysin gene (*lytA* [39](#R39){ref-type="bib"}), and each codes for an important virulence factor.

The antigenic variation appears to have arisen through the selective advantage that SAg escape mutants provide to the species *S*. *pyogenes*. This is perhaps the best evidence yet that the SAgs confer an advantage on the strain that produces it. Moreover, the ubiquitous expression and genetic variation tend to suggest that *smez*, more than other SAgs, significantly enhances the survival of group A *Streptococci* in general and thus might be linked to increased virulence and streptococcal disease severity. The *smez* locus may provide an important genotyping locus to examine virulence and disease susceptibility, and may also offer a potential target for streptococcal vaccine development.
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*Abbreviations used in this paper:* ET, electrophoresis type; GAS, group A *Streptococcus*; GST, glutathione *S*-transferase; KD, Kawasaki disease; MNT, M-nontypable; SAg, superantigen; SE, staphylococcal enterotoxin; SF, scarlet fever; SID, severe invasive disease; SMEZ, streptococcal mitogenic exotoxin; SPE, streptococcal pyrogenic exotoxin; STLS, streptococcal toxic shock-like syndrome; TSS, toxic shock syndrome.

###### 

Genotyping of Streptococcal Isolates

  Group 1: Isolates collected from various parts of New Zealand between 1976 and 1996   Group 2: Isolates collected from South Auckland schools in 1998                                                                                                                                     
  ------------------------------------------------------------------------------------- ----------------------------------------------------------------- -------- ----- ------------- ---- ---- ---- ---- ---- --------- --------- ------- --- -------- ---- ---- ---- ---- ---- ---- ---- ---------
  FP 1943                                                                               A                                                                 M53      ts    ST            \+   \+   −    \+   −    n.d.      4202      3310    A   NZ5118   ts   ST   \+   \+   −    \+   \+   smez-14
  FP 2658                                                                               A                                                                 M59      ts    ST            \+   \+   −    \+   −    smez-12   4202(2)   3310    A   NZ5118   ts   ST   \+   \+   −    \+   \+   smez-14
  FP 4223                                                                               A                                                                 M80      ts    ST            \+   \+   −    \+   \+   n.d.      9606      2252    A   MNT      ts   ST   \+   \+   −    \+   −    smez-6
  FP 5417                                                                               A                                                                 M41      ts    ST            \+   \+   −    \+   \+   smez-15   9639      2184    A   MNT      ts   ST   \+   \+   \+   \+   \+   smez-3
  FP 5847                                                                               A                                                                 M1       ts    ST            \+   \+   −    \+   \+   n.d.      9779      3230    A   emm56    ts   ST   \+   \+   −    \+   \+   smez-11
  FP 5971                                                                               A                                                                 M57      ts    ST            \+   \+   \+   \+   −    n.d.      9893      6144    A   PT180    ts   ST   \+   \+   \+   \+   \+   smez-4
  1/5045                                                                                A                                                                 M4       ts    ST            \+   \+   −    \+   \+   smez-8    9894      6564    A   emm59    ts   ST   \+   \+   −    \+   \+   n.d.
  79/1575                                                                               A                                                                 M1       ts    Tcarriage     \+   \+   \+   \+   \+   smez-1    10019     6264    A   emm44    ts   ST   \+   \+   \+   \+   −    smez-19
  81/3033                                                                               A                                                                 M12      ts    ST            \+   \+   \+   \+   \+   n.d.      10028     9366    A   emm41    ts   ST   \+   \+   −    \+   \+   n.d.
  82/20                                                                                 A                                                                 M4       sk    Ulcer         \+   \+   −    \+   \+   n.d.      10134     1880    A   ST4547   ts   ST   \+   \+   −    \+   −    smez-5
  82/532                                                                                A                                                                 M12      ts    ST            \+   \+   \+   \+   \+   n.d.      10303     3564    A   emm59    ts   ST   \+   \+   −    \+   −    smez-12
  82/675                                                                                A                                                                 NZ1437   ws    Wound         \+   \+   −    \+   \+   n.d.      10307     4850    A   NZ5118   ts   ST   \+   \+   −    \+   \+   n.d.
  84/141                                                                                A                                                                 M12      ts    ST            \+   \+   \+   \+   \+   n.d.      10438     4904    A   ST3018   ts   ST   \+   \+   −    \+   \+   smez-24
  84/1733                                                                               A                                                                 M4       ts    ST            \+   \+   −    \+   \+   n.d.      10463     TSP     A   emm49    ts   ST   \+   \+   −    \+   −    smez-22
  84/781                                                                                A                                                                 NZ1437   ts    ST            \+   \+   −    \+   \+   n.d.      10649     11510   A   ST2267   ts   ST   \+   \+   −    \+   \+   smez-16
  85/1                                                                                  A                                                                 M12      ts    ST            \+   \+   −    \+   \+   n.d.      10730     11503   A   MNT      ts   ST   \+   \+   −    \+   −    n.d.
  85/167                                                                                A                                                                 M12      ts    ST            \+   \+   \+   \+   \+   n.d.      10742     3374    A   ST809    ts   ST   \+   \+   −    \+   \+   n.d.
  85/314                                                                                A                                                                 NZ1437   ws    Wound         \+   \+   −    \+   \+   n.d.      10761     3254    A   MNT      ts   ST   \+   \+   −    \+   −    smez-6
  85/437                                                                                A                                                                 M81      ws    Inf. eczema   \+   \+   −    \+   \+   smez-8    10763     6614    A   PT3875   ts   ST   \+   \+   −    \+   −    smez-18
  85/722                                                                                A                                                                 n.d.     ?     ?             \+   \+   −    \+   −    smez-23   10782     4850    A   MNT      ts   ST   \+   \+   \+   \+   \+   n.d.
  86/435                                                                                A                                                                 M4       ts    RF            \+   \+   −    \+   \+   smez-8    10791     10290   A   MNT      ts   ST   \+   \+   \+   \+   \+   n.d.
  87/169                                                                                A                                                                 M12      ts    ST            \+   \+   \+   \+   \+   smez-3    10792     10308   A   MNT      ts   ST   \+   \+   \+   \+   −    smez-6
  87/19                                                                                 A                                                                 M12      ts    ST            \+   \+   \+   \+   \+   smez-3    10846     8854    A   NZ1437   ts   ST   \+   \+   −    \+   \+   n.d.
  87/781                                                                                A                                                                 M12      ts    ST            \+   \+   −    \+   \+   n.d.      10902     6264    A   NZ5118   ts   ST   \+   \+   −    \+   \+   n.d.
  88/627                                                                                A                                                                 M12      sk    Wound         \+   \+   −    \+   −    n.d.      10989     5194    A   PT2841   ts   ST   \+   \+   −    \+   −    smez-20
  89/22                                                                                 A                                                                 M12      ts    Fever         \+   \+   −    \+   \+   n.d.      11070     1434    A   emm65    ts   ST   \+   \+   \+   −    −    n.d.
  89/25                                                                                 A                                                                 M12      ur    Erysipelas    \+   \+   \+   \+   \+   n.d.      11072     1880    A   ST4547   ts   ST   \+   \+   −    \+   −    smez-5
  89/26                                                                                 A                                                                 M1       ts    AGN           \+   \+   −    \+   \+   n.d.      11083     4358    A   MNT      ts   ST   \+   \+   −    \+   −    n.d.
  89/54                                                                                 A                                                                 NZ1437   ts    ST            \+   \+   −    \+   \+   n.d.      11093     9791    A   MNT      ts   ST   \+   \+   \+   \+   \+   n.d.
  90/306                                                                                A                                                                 M5       ear   Otorrhea      \+   \+   −    \+   \+   smez-4    11152     2030    A   PT2612   ts   ST   \+   \+   \+   −    −    n.d.
  90/424                                                                                A                                                                 M4       ts    ST            \+   \+   −    \+   \+   n.d.      11222     4928    A   NZ5118   ts   ST   \+   \+   \+   \+   \+   n.d.
  91/542                                                                                A                                                                 M12      ts    ST            \+   \+   −    \+   \+   n.d.      11227     8854    A   emm14    ts   ST   \+   \+   −    \+   −    smez-21
  94/11                                                                                 A                                                                 NZ1437   ps    Abscess       \+   \+   \+   \+   \+   n.d.      11244     2252    A   ST4547   ts   ST   \+   \+   −    \+   −    smez-5
  94/229                                                                                A                                                                 M49      hvs   Endometr.     \+   \+   \+   −    −    n.d.      11276     4524    A   MNT      ts   ST   \+   \+   −    −    −    n.d.
  94/330                                                                                A                                                                 M4       ts    SF            \+   \+   −    \+   \+   n.d.      11299     2950    A   emm80    ts   ST   \+   \+   −    \+   \+   smez-9
  94/354                                                                                A                                                                 M12      ts    ST            \+   \+   −    \+   \+   n.d.      11574     3186    A   ST809    ts   ST   \+   \+   −    \+   \+   smez-7
  94/384                                                                                A                                                                 M4       sk    Wound         \+   \+   −    \+   \+   n.d.      11580     3280    A   emm53    ts   ST   \+   \+   −    \+   −    smez-10
  94/712                                                                                A                                                                 NZ1437   ws    Cellulitis    \+   \+   −    \+   \+   n.d.      11610     2424    A   emm57    ts   ST   \+   \+   \+   −    −    n.d.
  95/127                                                                                A                                                                 NZ1437   bc    Cellulitis    \+   \+   −    \+   \+   n.d.      11646     1880    A   ST4547   ts   ST   \+   \+   −    \+   −    n.d.
  95/31                                                                                 A                                                                 NZ1437   ws    Abscess       \+   \+   −    \+   \+   smez-13   11681     3564    A   emm12    ts   ST   \+   \+   −    \+   \+   smez-3
  95/31(2)                                                                              A                                                                 NZ1437   ws    Abscess       \+   \+   −    \+   \+   n.d.      11686     5528    A   PT5757   ts   ST   \+   \+   −    \+   \+   smez-17
  95/361                                                                                A                                                                 NZ1437   ps    Abscess       \+   \+   −    \+   \+   n.d.      11745     12397   A   emm59    ts   ST   \+   \+   −    \+   −    n.d.
  96/1                                                                                  A                                                                 n.d.     ?     ?             \+   \+   −    \+   \+   n.d.      11789     1568    A   MNT      ts   ST   \+   \+   −    \+   −    smez-6
  96/364                                                                                A                                                                 NZ1437   bc    Burns         \+   \+   −    \+   \+   n.d.      11802     3266    A   MNT      ts   ST   \+   \+   −    \+   −    n.d.
  96/551                                                                                A                                                                 M4       eye   Eye infect.   \+   \+   −    \+   \+   n.d.      11869     2950    A   ST4547   ts   ST   \+   \+   −    \+   −    smez-5
  96/610                                                                                A                                                                 M4       ts    SF            \+   \+   −    \+   \+   n.d.      11961     4916    A   MNT      ts   ST   \+   \+   −    \+   −    n.d.
  D21                                                                                   A                                                                 M1       ts    Tcarriage     \+   \+   −    \+   \+   n.d.      12015     12373   A   emm59    ts   ST   \+   \+   \+   \+   −    n.d.
  RC4063                                                                                C                                                                 --       ts    ST            \+   −    −    −    −    −         7625      8215    B   --       ts   ST   \+   −    −    −    −    −
  SP9205                                                                                C                                                                 --       ts    ST            \+   −    −    −    −    −         8011      3238    B   --       ts   ST   \+   −    −    −    −    −
  NI6174                                                                                G                                                                 --       ts    ST            \+   −    −    −    −    −         10388     1653    G   --       ts   ST   \+   −    −    −    −    −
  NI6192                                                                                B                                                                 --       ts    ST            \+   −    −    −    −    −         OI2633    5395    B   --       ts   ST   \+   −    −    −    −    −
  VC4141                                                                                G                                                                 --       ts    ST            \+   −    −    −    −    −                                                                           

The isolates were collected in New Zealand between 1976 and 1996 (group 1) and from South Auckland schools in 1998 (group 2) from patients with varying diseases. The results are based on PCR analysis using purified genomic DNA and specific primers for each of the *sag* genes. The non-GAS are: B, *S. agalactiae*; C, *S. equis*; G, *Streptococcus spp*. Site and disease abbreviations are as follows: ts, throat site; ws, wound site; sk, skin; ps, pus site; hvs, high vaginal site; bc, blood culture; ST, sore throat; RF, rheumatic fever; AGN, acute glomerulonephritis; T carriage, throat carriage. n.d., not determined.

###### 

List of All smez Variants Identified To Date

  Gene      Protein   pI     P~50~   M/emm type        Accession no.
  --------- --------- ------ ------- ----------------- ---------------
                             pg/ml                     
  smez-1    SMEZ-1    5.4    0.1     M1                --
  smez-2    SMEZ-2    6.98   0.02    n.d.              AF086626
  smez-3    SMEZ-3    6.98   0.25    MNT, emm12, M12   AF143653
  smez-4    SMEZ-4    5.73   n.d.    PT180, M5         AF143654
  smez-5    SMEZ-5    5.17   0.7     ST4547            AF143655
  smez-6    n.f.      --     --      MNT               AF143656
  smez-7    SMEZ-7    6.14   0.3     ST809             AF143657
  smez-8    SMEZ-8    5.17   0.25    M4, M81           AF143658
  smez-9    SMEZ-9    8.86   0.2     emm80, M80        AF143659
  smez-10   SMEZ-10   5.4    n.d.    emm53, M53        AF143660
  smez-11   SMEZ-11   8.86   n.d.    emm56             AF143661
  smez-12   SMEZ-12   5.17   n.d.    emm59, M59        AF143662
  smez-13   SMEZ-13   6.14   0.2     NZ1437            AF143663
  smez-14   SMEZ-14   6.14   n.d.    NZ5118            AF143664
  smez-15   SMEZ-15   5.02   n.d.    M41               AF143665
  smez-16   SMEZ-16   7.82   n.d.    ST2267            AF143666
  smez-17   SMEZ-17   8.86   n.d.    PT5757            AF143667
  smez-18   SMEZ-18   9.62   n.d.    PT3875            AF143668
  smez-19   n.f.      --     --      emm44             AF143669
  smez-20   SMEZ-20   7.82   0.09    PT2841            AF143670
  smez-21   SMEZ-21   6.14   0.3     emm14             AF143671
  smez-22   SMEZ-22   6.98   0.3     emm49             AF143672
  smez-23   SMEZ-23   --     --      n.d.              AF143673
  smez-24   SMEZ-24   8.85   n.d.    ST3018            AF143674

*smez-6*, *smez-19*, and *smez-23* all have a single base pair deletion causing a frame shift. With the exception of *smez-3*, *smez-4*, and *smez-8*, all analyzed variants could be correlated to a single M/emm type. pI, calculated isoelectric point; P~50~, half-maximal mitogenic potency; n.d., not determined; n.f., nonfunctional (pseudogene).

###### 

DNA Sequence Alignment of smez Alleles

![](JEM992205.t3)

Only the 62 variable nucleotides (9.8% of the *smez* gene) are shown, of which 17 are point mutations for single alleles and 45 are common to 2 or more alleles. Some of the variable sites are linked together, building sequence blocks (shaded gray) within five distinct regions (I--IV). In region III, only two sequence combinations occur, correlating with the two major branches (groups A and B) of the *smez* family tree (see [Fig. 2](#F2){ref-type="fig"}). Combinations between sequence blocks within the other four regions in different alleles generate gene mosaics.

###### 

Amino Acid Alignment of SMEZ Alleles

![](JEM992205.t4)

Only the 31 variable residues are shown (14.9% of the mature SMEZ protein). The sequence blocks and mosaic structure seen in the DNA sequence alignment ([Table](#T3){ref-type="table"}) are also reflected in the amino acid sequence.

###### 

Neutralization Assay

![](JEM992205.t5)

Human sera from 100 healthy New Zealand donors were used to study the presence of antibodies neutralizing the mitogenic activity of recombinant SMEZ variants. The figures given are the percentage of inhibition compared with a reference test in which human serum was replaced by FCS. The table shows the results obtained with 20 selected sera. The remaining 80 sera all showed high neutralizing responses for the whole panel of variants.

![Southern blot analysis of genomic DNA with radiolabeled *smez*. HindIII-digested genomic DNA from various *Streptococcus* isolates was hybridized with a radiolabeled *smez* probe. Band A is a 1953-bp HindIII DNA fragment that carries the *smez* gene. Bands B and C are DNA fragments of ∼4 and 4.2 kbp, respectively, which both carry a *smez*-like region. M1, *S*. *pyogenes* reference strain (M1 type, 700294; American Type Culture Collection); 2, isolate 9639 (MNT); 9, isolate 11789 (MNT); 7, isolate 11152 (PT2612 type); 21, isolate RC4063 (group C *Streptococcus*); 26, isolate 11070 (emm65 type); M, DNA marker lane; 50, isolate 4202 (NZ5118/M92 type); 57, isolate 94/229 (M49 type); 67, isolate 11610 (emm57 type); 92, isolate 95/127 (NZ1437/M89 type); and 100, isolate 94/330 (M4 type).](JEM992205.f1){#F1}

![*smez* gene family tree. The family tree was created using the PileUp program v8 (Genetic Computer Group) and is based on nucleotide sequence homology. The *smez* family can be divided into two major groups based on a conserved DNA region (region III). *smez-6*, *smez-19*, and *smez-23* are pseudogenes with a single base pair deletion causing a frame shift.](JEM992205.f2){#F2}

![Isoelectric focusing gel. 2 μg of purified recombinant toxin was run on a 5.5% polyacrylamide isoelectric focusing gel (pH 5--8). The gel shows significant variation of the isoelectric point between SMEZ variants. Toxins with low isoelectric points, such as rSMEZ-5 and rSMEZ-8, belong to group A of the SMEZ family. Members of group B are characterized by a more basic isoelectric point.](JEM992205.f3){#F3}

![Jurkat cell assay. Jurkat cells (bearing a Vβ8 TCR) and LG-2 cells were mixed with varying concentrations of recombinant toxin and incubated for 24 h, before SeI cells were added. After 1 d, 0.1 mCi \[^3^H\]thymidine was added and cells were counted after an additional 24 h. ○, unstimulated; ▿ , rSMEZ-1; ▴, rSMEZ-5; ▪, rSMEZ-20; ⋄, rSMEZ-21; and •, rSMEZ-22.](JEM992205.f4){#F4}
